| ALLO |
Allogene Therapeutics, Inc. |
72%
|
Reciprocal relationship from ALLO graph: y suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing… |
| ATYR |
aTyr Pharma, Inc. |
72%
|
Reciprocal relationship from ATYR graph: duce preclinical, clinical and commercial supplies of our product candidates. Other than some internal capacity to support preclinical activities, we do not h… |
| BCDA |
BioCardia, Inc. |
72%
|
Reciprocal relationship from BCDA graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BCDA graph: interruption, our ability to manage our domestic and foreign operations coul… |
| BIAF |
bioAffinity Technologies, Inc. |
72%
|
Reciprocal relationship from BIAF graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BIAF graph: ddition, in a patent infringement proceeding, a court may decide that a pate… |
| BIAFW |
BIAFW |
72%
|
Reciprocal relationship from BIAFW graph: e, handling, or disposal of these materials. In the event of contamination or injury, PPLS could be held liable for any resulting damages, and any liability … |
| BIOA |
BioAge Labs, Inc. |
72%
|
Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addi… |
| BNBX |
BNB Plus Corp. |
72%
|
Reciprocal relationship from BNBX graph: ices for the fiscal year ended September 30, 2024 includes 26% and 17% from two customers within our MDx Testing Services and Therapeutic DNA Production segme… |
| BNR |
Burning Rock Biotech Limited |
72%
|
Reciprocal relationship from BNR graph: ays (1) For the year ended December 31, 2025. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus have been endorsed by their adoption in ov… |
| BNTC |
Benitec Biopharma Inc. |
72%
|
Reciprocal relationship from BNTC graph: vestigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and inside… |
| CABA |
Cabaletta Bio, Inc. |
72%
|
Reciprocal relationship from CABA graph: and significant marketing efforts before we generate any revenue from product sales. Other programs of ours require additional discovery research and then pre… |
| CALC |
CalciMedica, Inc. |
72%
|
Reciprocal relationship from CALC graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CALC graph: vernmental bodies to limit the scope of patent protection both inside and ou… |
| CTMX |
CytomX Therapeutics, Inc. |
72%
|
Reciprocal relationship from CTMX graph: and adverse effect on our business, financial condition, results of operations and prospects. Our employees and independent contractors may engage in miscondu… |
| DNLI |
Denali Therapeutics Inc. |
72%
|
Reciprocal relationship from DNLI graph: pricing, availability, quality, and delivery schedules. Unexpected changes in tariffs, trade barriers, price and exchange controls, and other regulatory requi… |
| DSGN |
Design Therapeutics, Inc. |
72%
|
Reciprocal relationship from DSGN graph: bility of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to t… |
| ELVN |
Enliven Therapeutics, Inc. |
72%
|
Reciprocal relationship from ELVN graph: nce to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not pro… |
| FLGT |
Fulgent Genetics, Inc. |
72%
|
Reciprocal relationship from FLGT graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from FLGT graph: , information technology, and service companies may develop and sell competi… |
| GH |
Guardant Health, Inc. |
72%
|
Reciprocal relationship from GH graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from GH graph: biopsy space for therapy selection include Foundation Medicine, Inc., which was … |
| HOWL |
Werewolf Therapeutics, Inc. |
72%
|
Reciprocal relationship from HOWL graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from HOWL graph: any jurisdiction that we seek patent protection may diminish our ability to … |
| IMNM |
Immunome, Inc. |
72%
|
Reciprocal relationship from IMNM graph: ay in the future cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruc… |
| IRD |
Opus Genetics, Inc. |
72%
|
Reciprocal relationship from IRD graph: patent application. In addition, such interference, re-examination, opposition, post-grant review, inter partes review, supplemental examination, or revocation… |
| ITRM |
Iterum Therapeutics PLC |
72%
|
Reciprocal relationship from ITRM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ITRM graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from ITRM g… |
| JANX |
Janux Therapeutics, Inc. |
72%
|
Reciprocal relationship from JANX graph: that issued patents will afford sufficient protection of our product candidates or their intended uses against competitors, nor can there be any assurance tha… |
| KDK |
Kodiak AI, Inc. |
72%
|
Reciprocal relationship from KDK graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from KDK graph: services or employment agreements that contain non-disclosure and non-use prov… |
| KROS |
Keros Therapeutics, Inc. |
72%
|
Reciprocal relationship from KROS graph: d parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on… |
| MCRB |
Seres Therapeutics, Inc. |
72%
|
Reciprocal relationship from MCRB graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from MCRB graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from MCRB g… |
| NEO |
NeoGenomics, Inc. |
72%
|
Reciprocal relationship from NEO graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from NEO graph: rofitability. The market for genetic and molecular testing services is highly … |
| PEPG |
PepGen Inc. |
72%
|
Reciprocal relationship from PEPG graph: ntain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be a… |
| PHVS |
Pharvaris N.V. |
72%
|
Reciprocal relationship from PHVS graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the Un… |
| PRME |
Prime Medicine, Inc. |
72%
|
Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop… |
| PRPO |
Precipio, Inc. |
72%
|
Reciprocal relationship from PRPO graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PRPO graph: to be lawfully obtained or independently developed by a competitor or other … |
